Bupivacaine and Meloxicam
Class: Local Anesthetics
Chemical Name: (2R)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide;(2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
Molecular Formula: C36H56N4O2C14H13N3O4S2
CAS Number: 133687-22-6
Brands: Zynrelef
Warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
See full prescribing information for complete boxed warning.
Nonsteroidal anti-inflammatory agents (NSAIAs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.
Bupivacaine and meloxicam is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
NSAIAs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.
Introduction
Bupivacaine and meloxicam is a fixed combination containing bupivacaine, an amide local anesthetic, and meloxicam, a nonsteroidal anti-inflammatory agent (NSAIA).
Uses for Bupivacaine and Meloxicam
Bupivacaine and meloxicam has the following uses:
Bupivacaine and meloxicam is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty.
Bupivacaine and meloxicam has the following limitations of use:
Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures.
Bupivacaine and Meloxicam Dosage and Administration
General
The fixed combination of bupivacaine and meloxicam is available in the following dosage form(s) and strength(s):
Extended-release solution for soft tissue or periarticular instillation:
29.25 mg bupivacaine and 0.88 mg meloxicam per mL in 2.3, 7, 10.5, and 14 mL single-dose vials.
Dosage
It isessentialthat the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Adults
Dosage and Administration
Bupivacaine and meloxicam extended-release solution is administered by soft tissue or periarticular instillation; the drug should not be administered via epidural, intrathecal, intravascular or intra-articular routes, or used in regional nerve block, or pre-incisional or pre-procedural locoregional anesthetic techniques.
Bupivacaine and meloxicam extended-release ...
